Introduction {#s1}
============

Under physiological conditions, the endothelial layer of the vessels does not support a firm interaction with circulating leukocytes. In response to various injurious signals, expression of adhesion molecules by endothelial cells allows attraction, retention, and trans-membrane migration of leukocytes, thereby initiating vascular inflammation^\[[@b1]\]^. This pathophysiological process constitutes a pivotal step in the pathogenesis of a host of cardiovascular diseases including atherosclerosis^\[[@b2]\]^, pulmonary hypertension^\[[@b3]\]^, and myocardial infarction^\[[@b4]\]^.

Adhesion of leukocytes to the vessel wall is mediated by a group of structurally and functionally diverse membrane proteins called adhesion molecules^\[[@b5]\]^. This family of proteins includes intercellular adhesion molecules (ICAMs), vascular adhesion molecules (VCAMs), and selectins. Previous studies indicated that each adhesion molecule preferentially mediates the adhesion of a sub-set of circulating leukocytes to the vessel wall. For instance, *P*-selectin is known to specifically support the adhesion of platelets while ICAM-1 is necessary for the adhesion of lymphocytes^\[[@b6]-[@b7]\]^. While the basal expression level of *P*-selectin is low in endothelial cells, its transcription rate can be rapidly turned on by a number of pro-inflammatory factors including tumor necrosis factor (TNF-*α*), lipopolysaccharide (LPS), and hypoxia.

Myocardin-related transcription factor A, or MRTF-A, was first identified as a co-factor for serum response factor (SRF) to promote the transcription of muscle-specific genes^\[[@b8]\]^. MRTF-A deficiency in mice does not disturb organogenesis, but seems to protect the rodents from atherosclerosis^\[[@b9]\]^, pulmonary hypertension^\[[@b10]\]^, and myocardial infarction^\[[@b11]\]^. In addition, *in vitro* studies conducted in cultured endothelial cells demonstrate that MRTF-A is required for the transactivation of *ICAM-1*, *VCAM-1*, and *E-selectin* genes^\[[@b12]\]^. We report here that MRTF-A is also responsible for *P*-selectin transactivation in TNF-*α* treated endothelial cells by recruiting the chromatin remodeling protein BRG1 to alter the chromatin structure.

Materials and methods {#s2}
=====================

Cell culture and treatment {#s2a}
--------------------------

Human immortalized umbilical vein endothelial cells (EAhy926, ATCC, Manassas, VA, USA) were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone). Prior to treatment, cells were serum starved overnight and then treated with TNF-*α* (R&D, Minneapolis, MN, USA).

Plasmids, transient transfection, and reporter assay {#s2b}
----------------------------------------------------

FLAG-tagged MRTF-A construct, FLAG-tagged BRG1 construct, *P*-selectin promoter-luciferase construct (-1379/-13), short hairpin RNA (shRNA) construct for MRTF-A, small interfering RNA (siRNA) sequences for human MRTF-A and BRG1 have been previously described^\[[@b12]-[@b15]\]^. Transient transfections were performed with Lipofectamine 2000 (Invitrogen). Luciferase activities were assayed 24-48 hours after transfection using a luciferase reporter assay system (Promega, Madison, WI, USA). Experiments were routinely performed in triplicate wells and repeated three times.

Protein extraction and Western blotting assays {#s2c}
----------------------------------------------

Whole cell lysates were obtained by re-suspending cell pellets in RIPA buffer (50 mmol/L Tris pH7.4, 150 mmol/L NaCl, 1% Triton X-100) with freshly added protease inhibitors (Roche, Burgess Hill, west Sussex, UK). Western blot analyses were performed with anti-MRTF-A, anti-BRG1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-*β*-actin (Sigma, St. Louis, MO, USA) antibodies.

RNA isolation and real-time PCR {#s2d}
-------------------------------

RNA was extracted with the RNeasy RNA isolation kit (Qiagen). Reverse transcriptase reactions were performed using a SuperScript First-strand Synthesis System (Invitrogen). Real-time PCR was performed on an ABI Prism 7500 system. Primers and Taqman probes, used for real-time reactions, were purchased from Applied Biosystems.

Chromatin Immunoprecipitation (ChIP) {#s2e}
------------------------------------

Chromatin Immunoprecipitation (ChIP) assays were performed essentially as described before^\[[@b16]\]^. In brief, chromatin in control and treated cells were cross-linked with 1% formaldehyde. Cells were incubated in lysis buffer (150 mmol/L NaCl, 25 mmol/L Tris pH 7.5, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) supplemented with a protease inhibitor tablet and PMSF. DNA was fragmented into ∼500 bp pieces using a Branson 250 sonicator. Aliquots of lysates containing 200 *μ*g of protein were used for each immunoprecipitation reaction with anti-MRTF-A, anti-BRG1, anti-NF-*κ*B/p65 (Santa Cruz Biotechnology), anti-acetyl histone H3, and anti-trimethylated histone H3K4 (Millipore, Billerica, MA, USA). Precipitated genomic DNA was amplified by real-time PCR using previously described primers^\[[@b17]\]^.

Statistical analysis {#s2f}
--------------------

One-way ANOVA with *post-hoc* Scheffe analyses were performed using an SPSS package. P values smaller than .05 were considered statistically significant.

Results {#s3}
=======

MRTF-A activates *P*-selectin transcription in endothelial cells {#s3a}
----------------------------------------------------------------

We have previously shown that MRTF-A mediates the transactivation of *ICAM-1*, *VCAM-1*, and *E-selectin* genes in endothelial cells in response to the stimulation of oxLDL^\[[@b12]\]^ and hypoxia^\[[@b10]\]^. Since *P*-selectin is also involved in the interaction between vascular endothelium and circulating leukocytes, we hypothesized that MRTF-A might activate *P*-selectin transcription. We transfected a *P-selectin* promoter-luciferase fusion construct into EAhy926 cells with or without an MRTF-A expression construct. As shown in [***Fig. 1A***](#f01){ref-type="fig"}, MRTF-A up-regulated *P-selectin* promoter activity in a dose-dependent manner. In addition, MRTF-A markedly enhanced the activation of the *P-selectin* promoter by TNF-*α* ([***Fig. 1B***](#f01){ref-type="fig"}). On the contrary, knockdown of MRTF-A expression by a shRNA plasmid attenuated TNF-*α* induced activation of the *P*-selectin promoter ([***Fig. 1C***](#f01){ref-type="fig"}). Therefore, MRTF-A can indeed activate *P*-selectin transcription in endothelial cells.

![MRTF-A is essential for the transactivation of *P-selectin* promoter by TNF-*α* in endothelial cells.\
A: A *P-selectin* promoter construct was transfected into EAhy926 with increasing amounts of MRTF-A expression construct. Luciferase activities were normalized to the control group and expressed as relative luciferase unit (RLU). B: A *P-selectin* promoter construct was transfected into EAhy926 with or without MRTF-A followed by treatment with TNF-*α*. Luciferase activities were normalized to the control group and expressed as RLU. C: A *P-selectin* promoter construct was transfected into EAhy926 with shRNA plasmid targeting MRTF-A (shMRTF-A) or a control shRNA plasmid (non-target) followed by treatment with TNF-*α*. Luciferase activities were normalized to the control group and expressed as RLU.](jbr-30-01-060-g001){#f01}

MRTF-A is essential for BRG1 recruitment {#s3b}
----------------------------------------

Next, we asked whether MRTF-A might be essential for the induction of endogenous *P*-selectin messages by TNF-*α* in endothelial cells. We used siRNA to deplete endogenous MRTF-A; MRTF-A depletion down-regulated *P*-selectin induction by more than 50% in the presence of TNF-*α* ([***Fig. 2A***](#f02){ref-type="fig"}). Furthermore, TNF-*α* stimulated the occupancy of MRTF-A on the *P-selectin* promoter ([***Fig. 2B***](#f02){ref-type="fig"}). Therefore, MRTF-A may be an activator of *P*-selectin transcription by directly binding to the *P-selectin* promoter.

Prior studies have demonstrated that the chromatin remodeling protein BRG1 is required for MRTF-A dependent transcription in vascular smooth muscle cells^\[[@b18]\]^, macrophages^\[[@b19]\]^, and endothelial cells^\[[@b20]\]^. BRG1 binding on the *P-selectin* promoter was up-regulated by TNF-*α*; depletion of MRTF-A with siRNA simultaneously blocked the binding of MRTF-A and BRG1 to the *P-selectin* promoter ([***Fig. 2B***](#f02){ref-type="fig"}). Collectively, these data suggest that MRTF-A might recruit BRG1 to activate *P*-selectin transcription.

![MRTF-A is essential for BRG1 recruitment.\
A: EAhy926 cells were transfected with siRNA targeting MRTF-A or scrambled siRNA (SCR) followed by treatment with TNF-*α*. The mRNA transcript levels of *P-selectin* were measured by qPCR. Knockdown efficiency of MRTF-A siRNA was verified by qPCR and Western blotting. B: EAhy926 cells were transfected with siRNA targeting MRTF-A, or scrambled siRNA (SCR), followed by treatment with TNF-*α*. ChIP assays were performed with anti-MRTF-A or anti-BRG1. Precipitated DNA was amplified by primers flanking the *P-selectin* gene proximal promoter.](jbr-30-01-060-g002){#f02}

BRG1 contributes to *P*-selectin transactivation {#s3c}
------------------------------------------------

To verify the functional interaction between MRTF-A and BRG1 in transactivating the *P-selectin* gene, we performed the following reporter assays. Co-expression of wild type (WT), but not an enzyme deficient (ED), form of BRG1 with MRTF-A additively activated the *P-selectin* promoter ([***Fig. 3A***](#f03){ref-type="fig"}). On the other hand, siRNA-mediated depletion of BRG1 ameliorated MRTF-A-induced *P-selectin* promoter activation ([***Fig. 3B***](#f03){ref-type="fig"}). Similarly, BRG1 WT instead of BRG1 ED enhanced activation of *P-selectin* promoter by TNF-*α* ([***Fig. 3C***](#f03){ref-type="fig"}). Finally, BRG1 silencing suppressed *P*-selectin promoter activation by TNF-*α* ([***Fig. 3D***](#f03){ref-type="fig"}). Together, these data suggest that BRG1 might be an integral part of TNF-*α*-induced, MRTF-A-mediated *P*-selectin transactivation.

![BRG1 is essential for the transactivation of *P-selectin* promoter by TNF-*α* in endothelial cells.\
A: A *P-selectin* promoter construct was transfected into EAhy926 with MRTF-A, wild type (WT) BRG1, or enzyme deficient (ED) BRG1. Luciferase activities were normalized to the control group and expressed as relative luciferase unit (RLU). B: A *P-selectin* promoter construct was transfected into EAhy926 with MRTF-A, siRNA targeting BRG1, or SCR. Luciferase activities were normalized to the control group and expressed as RLU. C: A *P-selectin* promoter construct was transfected into EAhy926 with WT BRG1 or ED BRG1 followed by treatment with TNF-*α*. Luciferase activities were normalized to the control group and expressed as RLU. D: A *P-selectin* promoter construct was transfected into EAhy926 with siRNA targeting BRG1 or SCR followed by treatment with TNF-*α*. Luciferase activities were normalized to the control group and expressed as RLU.](jbr-30-01-060-g003){#f03}

BRG1 alters the chromatin structure surrounding *P-selectin* promoter {#s3d}
---------------------------------------------------------------------

We then tackled the mechanism whereby BRG1 might contribute to *P*-selectin transactivation. As shown in [***Fig. 4A***](#f04){ref-type="fig"}, BRG1 depletion by siRNA down-regulated the induction of endogenous *P*-selectin mRNA transcripts by TNF-*α*. BRG1 siRNA also prevented the binding of BRG1 to the *P-selectin* promoter ([***Fig. 4B***](#f04){ref-type="fig"}). In the meantime, BRG1 silencing eliminated the enrichment of two preeminent histone markers indicative of transcriptional activation, namely acetylated histone H3 and trimethylated histone H3K4, on the *P-selectin* promoter.

![BRG1 modulates histone modification and NF-*κ*B binding on the *P-selectin* promoter.\
A: EAhy926 cells were transfected with siRNA targeting BRG1 or SCR followed by treatment with TNF-*α*. The mRNA transcript levels of *P-selectin* were measured by qPCR. Knockdown efficiency of BRG1 siRNA was verified by qPCR and Western blotting. B: EAhy926 cells were transfected with siRNA targeting BRG1 or SCR followed by treatment with TNF-*α*. ChIP assays were performed with anti-BRG1, anti-acetyl histone H3 (AcH3), and anti-methylated histone H3K4 (H3K4Me3). C: EAhy926 cells were transfected with siRNA targeting BRG1 or SCR followed by treatment with TNF-*α*. ChIP assays were performed with anti-BRG1 and anti-p65.](jbr-30-01-060-g004){#f04}

The sequence-specific transcription factor NF-*κ*B/p65 has been shown to mediate TNF-*α* induced *P*-selectin transcription^\[[@b21]\]^. Indeed, TNF-*α* stimulation promoted the binding of p65 on the *P-selectin* promoter in EAhy926 cells in a time course-dependent manner: significant p65 binding started to appear on the *P-selectin* promoter as early as three hours post-treatment, peaked at six hours and declined at nine hours ([***Fig. 4C***](#f04){ref-type="fig"}). BRG1 depletion, however, impaired p65 binding; without BRG1, p65 binding peaked less and declined more ([***Fig. 4C***](#f04){ref-type="fig"}). Combined, these data suggest that BRG1 might regulate *P*-selectin transcription by altering histone modification and p65 binding kinetics on the *P-selectin* promoter.

Discussion {#s4}
==========

We show evidence here that MRTF-A and BRG1 cooperate to activate *P-selectin* transcription in vascular endothelial cells. In light of our previous findings that suggest MRTF-A can activate the transcription of other adhesion molecules^\[[@b10],[@b12]\]^, these new data allude to the possibility that targeting MRTF-A in endothelial cells could alleviate leukocyte adhesion and thus vascular inflammation in human diseases^\[[@b22]\]^.

Our data suggest that MRTF-A activates *P-selectin* gene in endothelial cells. It is known that *P*-selectin expression is detected in platelets and that *P*-selectin is required for platelet function^\[[@b23]\]^; one wonders whether MRTF-A might also drive *P*-selectin expression in platelets. Indeed, Krause and colleagues have recently shown that MRTF-A, along with its family member MRTF-B, play essential roles in megakaryocyte maturation and platelet formation, acting as a co-factor for SRF^\[[@b24]\]^. It would be of great interest to determine whether the deficiency in platelet formation in *MRTF-A/B*-null mice can be rescued by the introduction of exogenous *P-selectin*.

Mounting evidence has made it abundantly clear that MRTF-A may act as a bridge between the epigenetic machinery and the basal transcription machinery^\[[@b14],[@b18],[@b20],[@b25]-[@b28]\]^. We show here that MRTF-A activates *P*-selectin by recruiting BRG1 to the promoter region. BRG1 can sense a number of pro-inflammatory stimuli, including LPS^\[[@b29]\]^, hypoxia^\[[@b30]\]^, nutrition excess^\[[@b31]\]^, and TNF-*α*^\[[@b13]\]^, to program cellular response. Of note, BRG1 is absolutely required for vasculogenesis, as germ line deletion of systemic *BRG1* or endothelial *BRG1* in mice causes lethality due to extensive defects of the vasculature^\[[@b32]\]^. On the other hand, adult mice with induced deletion of BRG1 in endothelial cells appear to be normal under physiological conditions^\[[@b33]\]^. Based on the current dataset, we speculate that mice with inducible deletion of endothelial BRG1 would be protected from inflammation-associated adverse cardiovascular episodes, likely as a consequence of dampened synthesis of adhesion molecules including *P*-selectin. This hypothesis should be tested in future studies to further validate the role of BRG1 *in vivo*.

Consistent with our previous findings that BRG1 could forge a crosstalk with histone modifying enzymes^\[[@b13],[@b20],[@b25],[@b31]\]^, we demonstrate here that BRG1 depletion led to the disappearance of acetylated histone H3 and methylated histone H3K4 from the *P-selectin* promoter. ChIP-sequencing analyses have indicated a co-enrichment of BRG1, AcH3, and H3K4Me3 in a cell-specific and differentiation-dependent manner^\[[@b34]-[@b35]\]^. It remains to be determined how BRG1 modulates histone modification on a genome-wide scale in inflammation-challenged endothelial cells. Another interesting finding in the present study is that BRG1 deficiency altered the binding of p65, although it is not clear whether this is due to BRG1-dependent nucleosome displacement or changes in histone modifications or both. Ding et al. recently found that vitamin D receptor (VDR) binding deprives certain regions of the chromatin of acetylated histones. This renders them less permissible for SMAD3 to bind, which explains the anti-fibrogenic effect of VDR^\[[@b36]\]^. BRG1 might operate in a similar mode to modulate p65 binding.

In summary, we report here an epigenetic mechanism by which MRTF-A regulates *P*-selectin transcription. Future investigations employing spatiotemporally controlled animal models and ChIP-seq analysis would shed more light on the role of MRTF-A in regulating the vascular transcriptome.
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